Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Valentis has completed dosing in its phase IIb trial of VLTS 934 for the treatment of patients suffering with a form of peripheral arterial disease, intermittent claudication, characterized by leg pain during exercise due to a lack of adequate blood flow
Subscribe to our email newsletter
In the trial 140 patients were randomized to receive either VLTS 934 or a saline placebo. The primary endpoint of the trial is improvement in exercise tolerance 90 days after treatment. Valentis anticipates that it will have efficacy results from the trial in July 2006.
“Based on VLTS 934’s prior safety data, the significant improvements from baseline in all efficacy measures in the prior phase IIa trial and the favorable results observed in the phase IIb interim analysis, we believe the phase IIb trial will be successful,” commented Benjamin McGraw, III, chairman of Valentis.
The market for a safe and efficacious product to treat intermittent claudication has been estimated to be in excess of $1 billion. According to the company, approximately 5% of adults in the US over age of 55 suffer from the intermittent claudication.